Physician profile
Brian Burnett
NPI 1326418807
$2,133.55
in general payments reported to CMS, 2019-2025
24 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $459 · 2023: $377 · 2024: $411 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $437.44 | 2023-2025 | Collagenase Santyl, Renasys Touch, Iodosorb Ointment 40g USA |
| Medtronic, INC. | $385.41 | 2021-2024 | Intellis Adaptivestim |
| Abbvie INC. | $336.24 | 2021-2022 | |
| Allergan, INC. | $136.84 | 2021-2022 | |
| Kci USA, INC. | $107.35 | 2022-2023 | Activ.A.C. |
| Biowound Solutions, INC. | $87.01 | 2025 | Bio-Connekt |
| Saol Therapeutics INC. | $84.64 | 2021 | |
| Collegium Pharmaceutical, INC. | $66.91 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $64.07 | 2023-2024 | Nuzyra |
| Biodelivery Sciences International, INC. | $54.01 | 2021 | |
| Grt US Holding, INC. | $53.51 | 2022 | |
| Boston Scientific Corporation | $43.90 | 2024 | Infinion 16 |
| Acacia Pharma INC | $40.29 | 2021-2022 | |
| Revance Therapeutics, INC. | $37.02 | 2025 | Daxxify |
| Tersera Therapeutics LLC | $32.17 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $26.55 | 2025 | Activ.A.C., Promogran Prisma |
| Musculoskeletal Transplant Foundation INC. | $24.85 | 2023 | |
| Reprise Biomedical, INC. | $22.62 | 2025 | Miro3d |
| Nevro Corp. | $20.04 | 2023 | Senza |
| Amgen INC. | $18.57 | 2021 | |
| Eisai INC. | $14.42 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.12 | 2022 | |
| Organogenesis INC. | $13.57 | 2023 | Puraply |
| Lilly USA, LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.